Medscape InDiscussion: Psoriatic Arthritis

Clinical experts in rheumatology and integrative medicine discuss the realm of wellness in psoriatic arthritis care. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/959139). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources American College of Rheumatology https://www.rheumatology.org/ NIH: Science-Based Health & Wellness Resources for Your Community https://www.nih.gov/health-information/science-based-health-wellness-resources-your-community National Psoriasis Foundation: Living With Psoriatic Arthritis https://www.psoriasis.org/living-with-psoriatic-arthritis/ Definition of Wellness Why Mindfulness/Meditation Is a 'No-Brainer' for Health-Care Professionals https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572932/ Exploring This Issue: Whole-Person, Whole-Systems Health and Healing https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533648/ Quality-of-Life Measures Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10) Progress in Assessing Physical Function in Arthritis: PROMIS Short Forms and Computerized Adaptive Testing https://www.jrheum.org/content/36/9/2061.long 12-Item Short Form Survey (SF-12) Psychometric Evaluation of the 12-Item Short-Form Health Survey (SF-12) in Osteoarthritis and Rheumatoid Arthritis Clinical Trials https://pubmed.ncbi.nlm.nih.gov/11519772/ Patterns of Eating and Effect on Inflammation Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/29926091/ Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: Is Al Inflammation the Same? https://www.sciencedirect.com/science/article/pii/S0049017216300646?via%3Dihub Stress and Pain Pain and Affective Distress in Arthritis: Relationship to Immunity and Inflammation https://pubmed.ncbi.nlm.nih.gov/30669892/ The Psychosocial Burden of Psoriatic Arthritis https://pubmed.ncbi.nlm.nih.gov/28802776/ Sleep and Effect on Immune System The Sleep-Immune Crosstalk in Health and Disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689741/

What steps do these busy clinicians take to keep their patients trending toward the healthy side of the health-illness continuum? Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/959141). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources Why Mindfulness/Meditation Is a 'No-Brainer' for Health-Care Professionals https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572932/ Exploring This Issue: Whole-Person, Whole-Systems Health and Healing https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533648/ American College of Rheumatology https://www.rheumatology.org/ NIH National Center for Complementary and Integrative Health: Wellness and Well-Being https://www.nccih.nih.gov/health/wellness-and-well-being

Do patients with psoriatic arthritis get better care with a team approach? Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/959148). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources American Nurses Association: Advanced Practice Registered Nurse (APRN) https://www.nursingworld.org/practice-policy/workforce/what-is-nursing/aprn/ Addressing the Rheumatology Workforce Shortage: A Multifaceted Approach https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255118/ American College of Rheumatology: Psoriatic Arthritis https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis American College of Rheumatology: Rheumatology Workforce Study https://www.rheumatology.org/Learning-Center/Statistics/Workforce-Study

How clinical pharmacists can help counsel psoriatic arthritis patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/959149). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources The Role of Specialty Pharmacy in Boosting Psoriatic Arthritis Outcomes https://www.pharmacytimes.com/view/the-role-of-specialty-pharmacy-in-boosting-psoriatic-arthritis-outcomes Impact of clinical pharmacist on medication adherence among psoriasis patients: A randomized controlled study https://www.sciencedirect.com/science/article/pii/S2213398420302578 Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study https://www.pharmacypractice.org/index.php/pp/article/view/2312 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis https://www.rheumatology.org/Portals/0/Files/PsA-Guideline-2018.pdf

Elaine Husni, MD, MPH, and Anthony Fernandez, MD, PhD, discuss the aspects that make their combined rheumatology-dermatology clinic a success. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/959155). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: The Role of Combined Clinics https://link.springer.com/article/10.1007/s11926-018-0785-6 Clinicians' Perspectives of Shared Care of Psoriatic Arthritis and Psoriasis Between Rheumatology and Dermatology: An Interview Study https://link.springer.com/article/10.1007/s10067-020-05391-y Early Recognition and Treatment Heralds Optimal Outcomes: The Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients https://link.springer.com/article/10.1007/s11926-017-0706-0 Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: Benefits and Challenges of Combined Rheumatology-Dermatology Clinics https://www.jrheum.org/content/44/5/693.long

Elaine Husni, MD, MPH, and Ana-Maria Orbai, MD, MHS, discuss the emerging and novel therapeutics in psoriatic arthritis and the impact that they will have on their patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/959157). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis https://www.rheumatology.org/Portals/0/Files/PsA-Guideline-2018.pdf EULAR Recommendations for the Management of Psoriatic Arthritis With Pharmacological Therapies: 2019 Update https://ard.bmj.com/content/79/6/700.1 Treatment Guidelines in Psoriatic Arthritis https://academic.oup.com/rheumatology/article/59/Supplement_1/i37/5802853 Bimekizumab in Patients with Active Psoriatic Arthritis: Results From a 48-Week, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)33161-7/fulltext

Drs Stanley Cohen and Alexis Ogdie-Beatty discuss minimal disease activity and the disease activity measures used in clinical trials as well as practice in treating psoriatic arthritis. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970781). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals. Resources Psoriatic Arthritis https://emedicine.medscape.com/article/2196539-overview A Proposed Revision to the ACR20: The Hybrid Measure of American College of Rheumatology Response https://www.rheumatology.org/Portals/0/Files/A%20Proposed%20Revision%20to%20the%20ACR20.pdf DAS28-CRP for Rheumatoid Arthritis https://reference.medscape.com/calculator/275/das28-crp-for-rheumatoid-arthritis ACR-FDA Summit https://www.rheumatology.org/Learning-Center/Educational-Activities/View/ID/1213 Measuring Minimal Disease Activity in Psoriatic Arthritis https://decisionpoint.medscape.com/rheumatology/viewarticle/951228 How Is the Severity of Psoriatic Arthritis and Psoriasis Usually Assessed? https://www.medscape.com/answers/2196539-155443/how-is-the-severity-of-psoriatic-arthritis-and-psoriasis-usually-assessed Standardizing the Monitoring of Outcome Measures https://www.medscape.com/viewarticle/741428 Patient Reported Outcomes in the Assessment of Minimal Disease and Remission https://decisionpoint.medscape.com/rheumatology/viewarticle/952950 Validating the SF-36 Health Survey Questionnaire in Patients With Psoriatic Arthritis https://pubmed.ncbi.nlm.nih.gov/9058658/ A Modified Version of the Health Assessment Questionnaire (HAQ) for Psoriatic Arthritis https://pubmed.ncbi.nlm.nih.gov/7586774/ Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and Its Potential as a Single-Item Outcome Measure in Clinical Practice https://pubmed.ncbi.nlm.nih.gov/29146740/ Psoriasis and Psoriatic Arthritis Multicenter Advancement Network https://www.ppacman.org/ Enthesitis: Workup and Severity Assessment https://decisionpoint.medscape.com/rheumatology/viewarticle/951227 Psoriatic Arthritis Treatment & Management https://emedicine.medscape.com/article/2196539-treatment Effects of Ustekinumab Versus Tumor Necrosis Factor Inhibition on Enthesitis: Results From the Enthesial Clearance in Psoriatic Arthritis (ECLIPSA) Study https://www.sciencedirect.com/science/article/abs/pii/S0049017218301501?via%3Dihub

Drs Stanley Cohen and Eric Ruderman discuss shared decision making strategies in psoriatic arthritis management. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970782). The topics and discussions are planned, produced, and reviewed independently of the advertiser. This podcast is intended only for US healthcare professionals. Resources Medscape Shared Decision Making https://www.medscape.org/shareddecisionmaking Psoriatic Arthritis https://emedicine.medscape.com/article/2196539-overview Treatment Strategies in PsA Management: Use of IL-17 Inhibitors https://decisionpoint.medscape.com/rheumatology/viewarticle/950788 Decision Strategies in PsA Management: Role of IL-23 Inhibitors https://decisionpoint.medscape.com/rheumatology/viewarticle/951718 Ixekizumab Prescribing Information https://uspl.lilly.com/taltz/taltz.html#pi GRAPPA Treatment Recommendations: 2021 Update https://www.jrheum.org/content/early/2022/03/10/jrheum.211331 Apremilast Prescribing Information https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Otezla/otezla_pi_english.pdf Psoriatic Arthritis Workup https://emedicine.medscape.com/article/2196539-workup#c6 Decision Strategies in PsA Management: Role of JAK Inhibitors https://decisionpoint.medscape.com/rheumatology/viewarticle/951717 Upadacitinib Prescribing Information https://www.rxabbvie.com/pdf/rinvoq_pi.pdf

Drs Stanley Cohen and Caylib Durand discuss the treatment paradigm for psoriatic arthritis and the role of methotrexate and other conventional synthetic disease-modifying antirheumatic drugs. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970783). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Psoriatic Arthritis https://emedicine.medscape.com/article/2196539-overview Psoriatic Arthritis: Expert Review and Commentary From Published Literature https://themedicalxchange.com/en/2021/11/23/3021-new-grappa-treatment-recommendations-for-psoriatic-arthritis/ GRAPPA Treatment Recommendations: 2021 Update https://www.jrheum.org/content/early/2022/03/10/jrheum.211331 What Is GRADE? https://bestpractice.bmj.com/info/us/toolkit/learn-ebm/what-is-grade/ Rheumatoid Arthritis (RA) Workup https://emedicine.medscape.com/article/331715-workup#c6 leflunomide (Rx) https://reference.medscape.com/drug/arava-leflunomide-343203 sulfasalazine (Rx) https://reference.medscape.com/drug/azulfidine-sulfasalazine-343280 AB0533 Combination of Methotrexate and Leflunomide Is Safe and Has Good Drug Retention Among Patients With Psoriatic Arthritis https://ard.bmj.com/content/80/Suppl_1/1298.1 apremilast (Rx) https://reference.medscape.com/drug/otezla-apremilast-999915 Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial https://onlinelibrary.wiley.com/doi/10.1002/art.40851 Psoriatic Arthritis Treatment & Management https://emedicine.medscape.com/article/2196539-treatment Iritis and Uveitis https://emedicine.medscape.com/article/798323-overview Paradoxical Gastrointestinal Effects of Interleukin-17 Blockers https://ard.bmj.com/content/79/9/1132

Drs Stanley Cohen and Atul Deodhar discuss cardiovascular risk in patients with psoriatic arthritis and the impact of effective treatment. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970784). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Prevalence of Metabolic Syndrome in Psoriatic Arthritis: Systematic Literature Review and Results From the CARMA Cohort https://journals.lww.com/jclinrheum/Abstract/2022/03000/Prevalence_of_Metabolic_Syndrome_in_Psoriatic.22.aspx Metabolic Syndrome https://emedicine.medscape.com/article/165124-overview What Is the Framingham Risk Score (FRS)? https://www.medscape.com/answers/2500032-166149/what-is-the-framingham-risk-score-frs 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines https://www.sciencedirect.com/science/article/pii/S0735109713060312?via%3Dihub What Is the Systematic Coronary Risk Evaluation (SCORE)? https://www.medscape.com/answers/2500032-166154/what-is-the-systematic-coronary-risk-evaluation-score Anti-inflammatory Therapy With Canakinumab for Atherosclerotic Disease https://www.nejm.org/doi/pdf/10.1056/nejmoa1707914 Colchicine in Patients With Chronic Coronary Disease https://www.nejm.org/doi/10.1056/NEJMoa2021372 The Effects of Tumour Necrosis Factor Inhibitors, Methotrexate, Non-steroidal Anti-inflammatory Drugs and Corticosteroids on Cardiovascular Events in Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis https://ard.bmj.com/content/74/3/480 Psoriatic Arthritis Medication https://emedicine.medscape.com/article/2196539-medication Efficacy and Safety of Selective TYK2 Inhibitor, Deucravacitinib, in a Phase II Trial in Psoriatic Arthritis https://ard.bmj.com/content/81/6/815 FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death

Diagnosing psoriatic arthritis can be a challenging endeavor. Drs Cohen and Gladman discuss how they approach early diagnosis, ruling out mimics, and the literature on the subject to help clinicians diagnose and treat psoriatic arthritis in clinic. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970785). The topics and discussions are planned, produced, and reviewed independently of the advertiser. This podcast is intended only for US healthcare professionals. Resources Psoriatic Arthritis https://emedicine.medscape.com/article/2196539-overview Observational Cohort Studies: Lessons Learnt From the University of Toronto Psoriatic Arthritis Program https://academic.oup.com/rheumatology/article/50/1/25/1789865 Psoriatic Arthritis https://pubmed.ncbi.nlm.nih.gov/4581554/ GRAPPA Treatment Recommendations: 2021 Update https://www.jrheum.org/content/early/2022/03/10/jrheum.211331 Psoriatic Arthritis: Performance of Rheumatologists in Daily Practice https://ard.bmj.com/content/61/3/219 The ClASsification for Psoriatic ARthritis (CASPAR) Criteria – A Retrospective Feasibility, Sensitivity, and Specificity Study https://www.jrheum.org/content/39/1/154 Toronto Psoriatic Arthritis Screening (ToPAS) Questionnaire: A Report From the GRAPPA 2009 Annual Meeting https://www.jrheum.org/content/jrheum/38/3/546.full.pdf Prevention of Metacarpophalangeal Joints Structure Damage in Patients With Psoriatic Arthritis Using Secukinumab https://clinicaltrials.gov/ct2/show/NCT03623867

Join Drs Cohen and Gibofsky as they step through a case of refractory psoriatic arthritis, discuss novel therapeutics, review latest clinical trials, and talk about the future in psoriatic arthritis. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970786). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Psoriatic Arthritis Workup https://emedicine.medscape.com/article/2196539-workup#c6 GRAPPA Treatment Recommendations: 2021 Update https://www.jrheum.org/content/49/6_Suppl_1/52.long Methotrexate in Psoriasis and Psoriatic Arthritis https://www.jrheum.org/content/96/31 Psoriatic Arthritis Medication https://emedicine.medscape.com/article/2196539-medication#4 Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients https://www.jrheum.org/content/47/6/854 Three JAK Inhibitors Get Boxed Warnings, Modified Indications https://www.medscape.com/viewarticle/958024 Effect of Tofacitinib on Patient-Reported Outcomes in Patients With Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors in the Phase III, Randomised Controlled Trial: OPAL Beyond https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340607/ Upadacitinib in Patients With Psoriatic Arthritis and an Inadequate Response to Non-biological Therapy: 56-Week Data From the Phase 3 SELECT-PsA 1 Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524381/ Multicentre, Randomised, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Naïve to Biological Disease-Modifying Antirheumatic Drug: Final Results by Week 52 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509529/ Improvement in Patient-Reported Outcomes in Patients With Psoriatic Arthritis Treated With Upadacitinib Versus Placebo or Adalimumab: Results From SELECT-PsA 1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572257/ Bimekizumab in Patients With Active Psoriatic Arthritis: Results From a 48-Week, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Trial https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(19)33161-7 A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment https://clinicaltrials.gov/ct2/show/NCT04908189

Tune in to hear Drs Stanley Cohen and Alexis Ogdie dive into new research on switching vs cycling medications in caring for patients with psoriatic arthritis, tight control in axSpA, and more. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984265). The topics and discussions are planned, produced, and reviewed independently of the advertisers. This podcast is intended only for US healthcare professionals. Resources 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients With PsA: Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry https://www.eventscribe.net/2022/ACRConvergence/index.asp?presTarget=2189995 Cycling or Swap Biologics and Small Molecules in Psoriatic Arthritis: Observations From a Real-life Single Center Cohort https://pubmed.ncbi.nlm.nih.gov/33879661/ Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis https://pubmed.ncbi.nlm.nih.gov/35428720/ Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial https://pubmed.ncbi.nlm.nih.gov/30747501/ EULAR 2023. European Congress of Rheumatology https://congress.eular.org/ GRAPPA Treatment Recommendations: 2021 Update https://pubmed.ncbi.nlm.nih.gov/35293339/ Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis https://pubmed.ncbi.nlm.nih.gov/30499246/ Effect of a Treatment Strategy of Tight Control for Rheumatoid Arthritis (the TICORA Study): A Single-blind Randomised Controlled Trial https://pubmed.ncbi.nlm.nih.gov/15262104/ Aiming at Low Disease Activity in Rheumatoid Arthritis With Initial Combination Therapy or Initial Monotherapy Strategies: The BeSt Study https://pubmed.ncbi.nlm.nih.gov/17083767/ Long-term Follow-up of Patients in the TIght COntrol of Inflammation in Early Psoriatic Arthritis (TICOPA) Trial https://pubmed.ncbi.nlm.nih.gov/31504996/ Efficacy of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: Results of the Open-label, Pragmatic, Cluster-randomised TICOSPA Trial https://pubmed.ncbi.nlm.nih.gov/33958325/ ASAS Health Index: The "All in One" for Spondyloarthritis Evaluation? https://pubmed.ncbi.nlm.nih.gov/33004479/ Central Sensitization Has Major Impact on Quality of Life in Patients With Axial Spondyloarthritis https://pubmed.ncbi.nlm.nih.gov/35033996/ ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update https://pubmed.ncbi.nlm.nih.gov/36270658/ Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists: A Retrospective Study in Three Health Systems https://acrabstracts.org/abstract/treatment-of-ankylosing-spondylitis-by-primary-care-physicians-and-rheumatologists-a-retrospective-study-in-three-health-systems/ Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study https://acrabstracts.org/abstract/multimorbidity-in-psoriasis-as-a-risk-factor-for-psoriatic-arthritis-a-population-based-study/ Comorbidities, Pain and Fatigue in Psoriatic Arthritis, Psoriasis and Healthy Controls: A Clinical Cohort Study https://pubmed.ncbi.nlm.nih.gov/33325531/

Experts Stanley Cohen and Arthur Kavanaugh give busy clinicians a rundown of what's new and noteworthy in the 2021 GRAPPA guidelines update. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984267). The topics and discussions are planned, produced, and reviewed independently of the advertisers. This podcast is intended only for US healthcare professionals. Resources Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated Treatment Recommendations for Psoriatic Arthritis 2021 https://pubmed.ncbi.nlm.nih.gov/35761070/ Etanercept Treatment of Psoriatic Arthritis: Safety, Efficacy, and Effect on Disease Progression https://pubmed.ncbi.nlm.nih.gov/15248226/ GRADE: An Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations https://pubmed.ncbi.nlm.nih.gov/18436948/ US Welcomes First Adalimumab Biosimilar, Amjevita https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita Impact of Clinical Domains Other Than Arthritis on Composite Outcomes in Psoriatic Arthritis: Comparison of Treatment Effects in the SEAM-PsA Trial https://pubmed.ncbi.nlm.nih.gov/35863864/

Drs Stanley Cohen and Christopher Ritchlin discuss advances in basic research for psoriatic arthritis, including new research using a humanized mouse model, combination therapy trials, and more. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984269). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Psoriatic Arthritis https://emedicine.medscape.com/article/2196539-overview Transcriptional Signature Associated With Early Rheumatoid Arthritis and Healthy Individuals at High Risk to Develop the Disease https://pubmed.ncbi.nlm.nih.gov/29584756/ DC-STAMP: A Key Regulator in Osteoclast Differentiation https://pubmed.ncbi.nlm.nih.gov/27018136/ Psoriatic Dactylitis: Current Perspectives and New Insights in Ultrasonography and Magnetic Resonance Imaging https://pubmed.ncbi.nlm.nih.gov/34204773/ Transcriptome Fact Sheet https://www.genome.gov/about-genomics/fact-sheets/Transcriptome-Fact-Sheet Tumor Necrosis Factor Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK482425/ Inverse Psoriasis https://www.psoriasis.org/inverse-psoriasis/ Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk https://acrabstracts.org/abstract/prediction-of-psoriatic-arthritis-tool-presto-development-and-performance-of-a-new-scoring-system-for-psoriatic-arthritis-risk/ Efficacy of Guselkumab, a Selective IL-23 Inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk Cohort (PAMPA): Protocol of a Randomised, Double-Blind, Placebo Controlled Multicentre Trial https://pubmed.ncbi.nlm.nih.gov/36564123/ Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review https://pubmed.ncbi.nlm.nih.gov/33301128/ Association Between Biological Immunotherapy for Psoriasis and Time to Incident Inflammatory Arthritis: A Retrospective Cohort Study https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00034-6/fulltext Prevention of Psoriatic Arthritis: The Next Frontier https://www.thelancet.com/pdfs/journals/lanrhe/PIIS2665-9913(23)00055-3.pdf Ultrasound Power Doppler and Gray Scale Joint Inflammation: What They Reveal in Rheumatoid Arthritis https://pubmed.ncbi.nlm.nih.gov/31304659/ Consensus Terminology for Preclinical Phases of Psoriatic Arthritis for Use in Research Studies: Results From a Delphi Consensus Study https://pubmed.ncbi.nlm.nih.gov/33589818/ Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift https://pubmed.ncbi.nlm.nih.gov/32602263/ Abatacept Reverses Subclinical Arthritis in Patients With High-Risk to Develop Rheumatoid Arthritis -- Results From the Randomized, Placebo-Controlled ARIAA Study in RA-at risk Patients https://acrabstracts.org/abstract/abatacept-reverses-subclinical-arthritis-in-patients-with-high-risk-to-develop-rheumatoid-arthritis-results-from-the-randomized-placebo-controlled-ariaa-study-in-ra-at-risk-patients/ Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial https://pubmed.ncbi.nlm.nih.gov/10972371/ Arthritis Mutilans https://pubmed.ncbi.nlm.nih.gov/23430715/ Usage of C-Reactive Protein Testing in the Diagnosis and Monitoring of Psoriatic Arthritis (PsA): Results From a Real-World Survey in the USA and Europe https://pubmed.ncbi.nlm.nih.gov/35032324/ Disease Modifying Anti-Rheumatic Drugs (DMARD) https://pubmed.ncbi.nlm.nih.gov/29939640/ Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis https://pubmed.ncbi.nlm.nih.gov/30499418/

Drs Stanley Cohen and Philip Mease review the 2022 ACR meeting topics, including new treatments, trial data, and what they think are the most pressing unmet needs in the field. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984271). The topics and discussions are planned, produced, and reviewed independently of the advertisers. This podcast is intended only for US healthcare professionals. Resources Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial https://pubmed.ncbi.nlm.nih.gov/10972371/ Group for Research and Assessment of Psoriasis and Psoriatic Arthritis https://www.grappanetwork.org/ American College of Rheumatology (ACR) Convergence https://www.rheumatology.org/Annual-Meeting Bimekizumab Treatment in Biologic DMARD-Naïve Patients With Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results From a Phase 3, Randomized, Placebo-Controlled, Active Reference Study https://acrabstracts.org/abstract/bimekizumab-treatment-in-biologic-dmard-naive-patients-with-active-psoriatic-arthritis-52-week-efficacy-and-safety-results-from-a-phase-3-randomized-placebo-controlled-active-reference-study/ Bimekizumab Treatment in Patients With Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study https://acrabstracts.org/abstract/bimekizumab-treatment-in-patients-with-active-psoriatic-arthritis-and-inadequate-response-to-tumor-necrosis-factor-inhibitors-16-week-efficacy-and-safety-from-a-phase-3-randomized-double-blind-pla/ Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-Naïve and TNFi-IR Patients With Active PsA: Pooled 16-Week Results From Phase 3 Randomized, Placebo-Controlled Studies https://acrabstracts.org/abstract/bimekizumab-improvements-in-efficacy-on-disease-activity-assessed-via-composite-endpoints-in-biologic-dmard-naive-and-tnfi-ir-patients-with-active-psa-pooled-16-week-results-from-phase-3-randomized/ Bimekizumab Versus Adalimumab in Plaque Psoriasis https://pubmed.ncbi.nlm.nih.gov/33891379/ A Head-to-Head Comparison of the Efficacy and Safety of Ixekizumab and Adalimumab in Biological-Naïve Patients With Active Psoriatic Arthritis: 24-Week Results of a Randomised, Open-Label, Blinded-Assessor Trial https://pubmed.ncbi.nlm.nih.gov/31563894/ GRAPPA Treatment Recommendations: 2021 Update https://pubmed.ncbi.nlm.nih.gov/35293339/ Deucravacitinib Prescribing Information https://packageinserts.bms.com/pi/pi_sotyktu.pdf Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Psoriatic Arthritis: 52-Week Results From a Randomized Phase 2 Trial https://acrabstracts.org/abstract/safety-and-efficacy-of-deucravacitinib-an-oral-selective-tyrosine-kinase-2-inhibitor-in-patients-with-psoriatic-arthritis-52-week-results-from-a-randomized-phase-2-trial/ Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis From the Phase 2 PAISLEY Study https://acrabstracts.org/abstract/deucravacitinib-reduces-interferons-b-cell-pathways-and-serological-biomarkers-of-systemic-lupus-disease-activity-pharmacodynamic-analysis-from-the-phase-2-paisley-study/ Nanobody: A Promising Toolkit for Molecular Imaging and Disease Therapy https://pubmed.ncbi.nlm.nih.gov/33464410/

Join Drs Stanley Cohen and Jonathan Kay as they discuss biosimilars in PsA, which will hit the US market this summer. They cover everything from working with your pharmacy to counseling patients. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984272). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Psoriatic Arthritis https://emedicine.medscape.com/article/2196539-overview Biosimilars for the Treatment of Psoriatic Arthritis https://pubmed.ncbi.nlm.nih.gov/31625769/ Biosimilars and the Extrapolation of Indications for Inflammatory Conditions https://pubmed.ncbi.nlm.nih.gov/28255229/ Adalimumab (Rx) https://reference.medscape.com/drug/amjevita-humira-adalimumab-343187 Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in Patients With Mild to Severe Psoriasis https://pubmed.ncbi.nlm.nih.gov/22229951/ Infliximab (Rx) https://reference.medscape.com/drug/remicade-inflectra-infliximab-343202 Rituximab (Rx) https://reference.medscape.com/drug/rituxan-truxima-rituximab-342243 Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site https://pubmed.ncbi.nlm.nih.gov/31587143/ Biosimilars to Bring a Bumper Crop of Adalimumab Options https://www.centerforbiosimilars.com/view/part-1-biosimilars-to-bring-a-bumper-crop-of-adalimumab-options The Difference Between an Interchangeable Biosimilar and One That Isn't https://www.centerforbiosimilars.com/view/the-difference-between-an-interchangeable-biosimilar-and-one-that-isn-t The Non-Medical Switching of Prescription Medications https://pubmed.ncbi.nlm.nih.gov/31081414/ Implementation of the Biologics Price Competition and Innovation Act of 2009 https://www.fda.gov/drugs/guidance-compliance-regulatory-information/implementation-biologics-price-competition-and-innovation-act-2009 Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36009592/ Certolizumab pegol (Rx) https://reference.medscape.com/drug/cimzia-certolizumab-pegol-343185

Join Drs Stanley Cohen and Joseph Merola as they discuss their real-world experience running combined rheum-derm clinics for psoriatic arthritis. Listen in to hear what they consider the key to success in private practice clinics. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984273). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Psoriatic Arthritis https://emedicine.medscape.com/article/2196539-overview Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal? https://pubmed.ncbi.nlm.nih.gov/34074683/ PPACMAN https://www.ppacman.org/ Management of Psoriasis and Psoriatic Arthritis in a Combined Dermatology and Rheumatology Clinic https://pubmed.ncbi.nlm.nih.gov/21904925/ Does Biologic Therapy Impact the Development of PsA Among Patients With Psoriasis? https://pubmed.ncbi.nlm.nih.gov/34615637/ Ankylosing Spondylitis and Undifferentiated Spondyloarthropathy https://emedicine.medscape.com/article/332945-overview Seronegative Spondyloarthropathy https://www.ncbi.nlm.nih.gov/books/NBK459356/ Utilization of the Psoriasis Epidemiology Screening Tool (PEST): A Risk Stratification Strategy for Early Referral of Psoriatic Arthritis Patients to Minimize Irreversible Erosive Joint Damage https://pubmed.ncbi.nlm.nih.gov/36214337/ Comparing the Visual Analog Scale and the Numerical Rating Scale in Patient-reported Outcomes in Psoriatic Arthritis https://pubmed.ncbi.nlm.nih.gov/33262305/ Tumor Necrosis Factor Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK482425/ Subacute Cutaneous Lupus Erythematosus (SCLE) https://emedicine.medscape.com/article/1065657-overview James Neil Gilliam, MD-The Career Arc of a Patient-oriented Translational Clinical Investigation Changemaker in Rheumatologic Skin Disease https://pubmed.ncbi.nlm.nih.gov/30023380/